OncLive TV

Hossein Borghaei, DO, MS, discusses the investigation of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Rosario Ligresti, MD, discusses the need for screening in pancreatic cancer. 

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

Paul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma. 

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.

Michael J. Wagner, MD, discusses known risk factors for developing angiosarcoma.

Michael J. Wagner, MD, discusses the standard of care for patients with angiosarcoma.

Michael J. Wagner, MD, discusses the challenge of diagnosing angiosarcoma.

Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

Vivek Subbiah, MD, discusses the FDA approval of dabrafenib plus trametinib for the treatment of patients with BRAF V600E–mutated unresectable or metastatic solid tumors.

Brad S. Kahl, MD, discusses unmet needs in mantle cell lymphoma.

Christine Ryan, MD, discusses the investigation of ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

John L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.

Toni Choueiri, MD, discusses the use of adjuvant pembrolizumab in renal cell carcinoma.

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

John H. Strickler, MD, discusses the rationale of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Ismail Jatoi, MD, discusses the importance of individualized care when deciding whether to omit sentinel lymph node biopsy in patients over the age of 70 with clinically node-negative, estrogen receptor–positive, HER2-negative breast cancer.

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.